Clinical trial
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or…
NCT00349518 · Bristol-Myers Squibb, Industry · Withdrawn
Key facts
| NCT number | NCT00349518 |
|---|---|
| Title | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL |
| Official title | A Phase II Study of Dasatinib (BMS-354825) in Subjects With Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 0 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2007 |
| First posted | Jul 7, 2006 |
| Last update posted | Feb 17, 2016 |
| Countries | Hungary, Italy, Netherlands, Poland, Russia, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: